JP7465945B2 - Ｂｅｔ阻害剤としてのヘテロ環式化合物 - Google Patents

Ｂｅｔ阻害剤としてのヘテロ環式化合物 Download PDF

Info

Publication number
JP7465945B2
JP7465945B2 JP2022500105A JP2022500105A JP7465945B2 JP 7465945 B2 JP7465945 B2 JP 7465945B2 JP 2022500105 A JP2022500105 A JP 2022500105A JP 2022500105 A JP2022500105 A JP 2022500105A JP 7465945 B2 JP7465945 B2 JP 7465945B2
Authority
JP
Japan
Prior art keywords
formula
compound
iiia
iia
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022500105A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538917A (ja
JP2022538917A5 (https=
Inventor
ミン ファム，ソン
チャクラバルティ，サルバジット
カンカナラ，ジャヤカント
チェン，ジーユン
ピー ミラー，クリス
ディ ペティグルー，ジェレミー
クマール ナヤク，アンジャン
バルデ，アヌプ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nuvation Bio Inc
Original Assignee
Nuvation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvation Bio Inc filed Critical Nuvation Bio Inc
Publication of JP2022538917A publication Critical patent/JP2022538917A/ja
Publication of JP2022538917A5 publication Critical patent/JP2022538917A5/ja
Application granted granted Critical
Publication of JP7465945B2 publication Critical patent/JP7465945B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2022500105A 2019-07-02 2020-07-01 Ｂｅｔ阻害剤としてのヘテロ環式化合物 Active JP7465945B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962870020P 2019-07-02 2019-07-02
US62/870,020 2019-07-02
US202063017547P 2020-04-29 2020-04-29
US63/017,547 2020-04-29
PCT/US2020/040566 WO2021003310A1 (en) 2019-07-02 2020-07-01 Heterocyclic compounds as bet inhibitors

Publications (3)

Publication Number Publication Date
JP2022538917A JP2022538917A (ja) 2022-09-06
JP2022538917A5 JP2022538917A5 (https=) 2023-07-11
JP7465945B2 true JP7465945B2 (ja) 2024-04-11

Family

ID=74065335

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500105A Active JP7465945B2 (ja) 2019-07-02 2020-07-01 Ｂｅｔ阻害剤としてのヘテロ環式化合物

Country Status (11)

Country Link
US (3) US11584756B2 (https=)
EP (1) EP3997070A4 (https=)
JP (1) JP7465945B2 (https=)
KR (1) KR102677015B1 (https=)
CN (1) CN114286818B (https=)
AU (1) AU2020299592A1 (https=)
CA (1) CA3145827A1 (https=)
CL (1) CL2021003513A1 (https=)
IL (1) IL289439B2 (https=)
MX (1) MX2022000050A (https=)
WO (1) WO2021003310A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3828183A4 (en) * 2018-07-25 2022-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
US11192900B2 (en) 2018-10-30 2021-12-07 Nuvation Bio Inc. Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
KR102677015B1 (ko) * 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물
WO2021222466A1 (en) * 2020-04-29 2021-11-04 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors
CA3224302A1 (en) 2021-06-29 2023-01-05 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
CN116135858B (zh) * 2021-11-16 2025-04-01 中国科学院广州生物医药与健康研究院 一种呋喃并吡啶酮类化合物及其应用
JP2025502064A (ja) * 2022-01-06 2025-01-24 デザイン セラピューティクス，インク． フリードライヒ運動失調症を治療するための化合物及び方法
CN114907335A (zh) * 2022-02-25 2022-08-16 陕西维世诺新材料有限公司 2-（苯并噻吩-2-基）苯并[d]惡唑衍生物、制备方法及应用
CN115028646B (zh) * 2022-05-31 2023-06-30 山东第一医科大学(山东省医学科学院) 一种含氮杂环类化合物、制备方法及在抗肿瘤制剂中的应用
WO2024138023A1 (en) * 2022-12-22 2024-06-27 Nuvation Bio Inc. Combination treatment of cancers with a bet inhibitor
AU2024329991A1 (en) * 2023-08-25 2026-03-05 Nuvation Bio Inc. Crystalline forms of a bet inhibitor
WO2025251167A1 (zh) * 2024-06-03 2025-12-11 中国科学院广州生物医药与健康研究院 一类溴结构域抑制活性的化合物及其用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
WO2009054952A2 (en) 2007-10-22 2009-04-30 Angion Biomedica Corp. Small molecule inhibitors of parp activity
JP2016533397A (ja) 2013-10-18 2016-10-27 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
WO2018130174A1 (zh) 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
JP2022509534A (ja) 2018-10-30 2022-01-20 ニューベイション・バイオ・インコーポレイテッド Ｂｅｔ阻害剤としてのヘテロ環式化合物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
EA015127B1 (ru) * 2006-06-08 2011-06-30 Эли Лилли Энд Компани Антагонисты мсн-рецепторов
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
ES2625945T3 (es) 2012-11-14 2017-07-21 Glaxosmithkline Llc Tieno[3,2-c]piridin-4(5H)-onas como inhibidores de bet
US9266891B2 (en) 2012-11-16 2016-02-23 Boehringer Ingelheim International Gmbh Substituted [1,2,4]triazolo[4,3-A]pyrazines that are BRD4 inhibitors
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
EP2970312B1 (en) 2013-03-11 2017-11-15 The Regents of The University of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
US9050346B2 (en) 2013-03-11 2015-06-09 Abbvie Inc. Bromodomain inhibitors
UY35395A (es) 2013-03-12 2014-10-31 Abbvie Inc Inhibidores de bromodominios tetracíclicos
HUE043568T2 (hu) 2013-03-14 2019-08-28 Glaxosmithkline Ip No 2 Ltd 2,3-diszubsztituált 1-acil-4-amino-1,2,3,4-tetrahidrokinolin származékok és bromodomén inhibitorokkénti felhasználásuk
US9670221B2 (en) 2013-03-14 2017-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Furopyridines as bromodomain inhibitors
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
WO2014206150A1 (en) 2013-06-28 2014-12-31 Abbvie Inc. Bromodomain inhibitors
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
WO2015099107A1 (ja) 2013-12-26 2015-07-02 塩野義製薬株式会社 含窒素６員環誘導体およびそれらを含有する医薬組成物
HUE041546T2 (hu) 2014-01-09 2019-05-28 Orion Corp Biciklusos heterociklusos származékvegyületek mint bromo doméninhibitorok
WO2015131005A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
PL3134403T3 (pl) 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
BR112017004580A2 (pt) 2014-09-12 2018-01-23 GlaxoSmithKline Intellectual Property composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento.
WO2016092375A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Corp. Substituted heterocycles as bromodomain inhibitors
EP3262045A1 (en) 2015-02-27 2018-01-03 The Regents of The University of Michigan 9h-pyrimido [4,5-b]indoles as bet bromodomain inhibitors
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
JP2018527293A (ja) 2015-06-16 2018-09-20 オリオン コーポレーション ブロモドメイン阻害剤としてのスピロ［シクロブタン−１，３’−インドリン］−２’−オン誘導体
ES2913048T3 (es) 2015-09-21 2022-05-31 Opna Immuno Oncology Sa Compuestos heterocíclicos y usos de estos
CA2998545A1 (en) 2015-09-22 2017-03-30 Glaxosmithkline Intellectual Property (No.2) Limited Pyridinone dicarboxamide for use as bromodomain inhibitors
EP3374350B1 (en) 2015-11-09 2022-01-05 Forge Therapeutics, Inc. Hydroxypyridinone and hydroxypyrimidinone based compounds for treating bacterial infections
WO2017103670A1 (en) 2015-12-14 2017-06-22 Zenith Epigenetics Lid. 1h-imidazo[4,5-b]pyridinyl and 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridinyl heterocyclic bet bromodomain inhibitors
PT3442972T (pt) 2016-04-15 2020-05-29 Abbvie Inc Inibidores de bromodomínio
EP3445750A4 (en) 2016-04-18 2019-11-27 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017223452A1 (en) 2016-06-23 2017-12-28 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
CN108069958A (zh) 2016-11-10 2018-05-25 凯惠科技发展(上海)有限公司 一种含氮杂环类化合物、其制备方法、药物组合物及应用
JP7840635B2 (ja) 2017-12-20 2026-04-06 貝達薬業股▲ふん▼有限公司 ブロモドメインタンパク質阻害剤である化合物、および組成物
US11427593B2 (en) 2018-01-16 2022-08-30 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Bromodomain inhibitor compound and use thereof
CN110041253B (zh) 2018-01-17 2022-03-29 上海翰森生物医药科技有限公司 吡啶类n-氧化衍生物及其制备方法和应用
EP3828183A4 (en) * 2018-07-25 2022-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
CN110964012B (zh) 2018-09-29 2021-08-13 上海凌达生物医药有限公司 一类稠杂环联芳基苄醇类化合物、制备方法和用途
US20230065463A1 (en) 2019-01-29 2023-03-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2020187123A1 (zh) 2019-03-17 2020-09-24 上海凌达生物医药有限公司 一类吡咯酰胺并吡啶酮类化合物、制备方法和用途
WO2020253711A1 (zh) 2019-06-17 2020-12-24 中国科学院上海药物研究所 一种吡咯并吡啶酮类化合物、其制备方法、其组合物和用途
KR102677015B1 (ko) * 2019-07-02 2024-06-19 누베이션 바이오 인크. Bet 억제제로서의 헤테로시클릭 화합물
WO2021222466A1 (en) 2020-04-29 2021-11-04 Nuvation Bio Inc. Heterocyclic compounds as bet inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022540A2 (en) 2002-09-06 2004-03-18 Fujisawa Pharmaceutical Co., Ltd. Pyridazinone and pyridone derivatives as adenosine antagonists
WO2009054952A2 (en) 2007-10-22 2009-04-30 Angion Biomedica Corp. Small molecule inhibitors of parp activity
JP2016533397A (ja) 2013-10-18 2016-10-27 セルジーン クオンティセル リサーチ，インク． ブロモドメイン阻害剤
WO2018130174A1 (zh) 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
JP2022509534A (ja) 2018-10-30 2022-01-20 ニューベイション・バイオ・インコーポレイテッド Ｂｅｔ阻害剤としてのヘテロ環式化合物

Also Published As

Publication number Publication date
KR102677015B1 (ko) 2024-06-19
WO2021003310A1 (en) 2021-01-07
CN114286818A (zh) 2022-04-05
EP3997070A4 (en) 2023-07-26
KR20220028072A (ko) 2022-03-08
JP2022538917A (ja) 2022-09-06
CA3145827A1 (en) 2021-01-07
IL289439B2 (en) 2026-04-01
CN114286818B (zh) 2024-09-20
AU2020299592A1 (en) 2022-02-17
IL289439B1 (en) 2025-12-01
IL289439A (en) 2022-02-01
MX2022000050A (es) 2022-05-24
US20230339964A1 (en) 2023-10-26
US11584756B2 (en) 2023-02-21
BR112021026668A2 (pt) 2022-02-15
US20250276978A1 (en) 2025-09-04
EP3997070A1 (en) 2022-05-18
US20210002293A1 (en) 2021-01-07
CL2021003513A1 (es) 2022-10-28

Similar Documents

Publication Publication Date Title
JP7465945B2 (ja) Ｂｅｔ阻害剤としてのヘテロ環式化合物
CA3226720A1 (en) Kras g12d inhibitors and uses thereof
CA3216163A1 (en) Carboxy-benzimidazole glp-1r modulating compounds
US9556171B2 (en) Certain protein kinase inhibitors
US11192900B2 (en) Substituted 1,6-dihydropyridinones and 1,2-dihydroisoquinolinones as bet inhibitors
RU2633694C2 (ru) Дейтерированный фениламинопиримидин и фармацевтическая композиция, содержащая такое соединение
JP2022544516A (ja) キナーゼ阻害剤としてのヘテロ環化合物
JP7384536B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
KR20190098266A (ko) 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용
WO2021222466A1 (en) Heterocyclic compounds as bet inhibitors
CN117651703A (zh) 取代的氨基甲酸大环化合物及其相关治疗方法
CN113045569B (zh) 用作ret激酶抑制剂的化合物及其应用
CN116134022A (zh) Atr抑制剂和其用途
EA048322B1 (ru) Гетероциклические соединения в качестве ингибиторов bet
BR112021026668B1 (pt) Compostos heterocíclicos como inibidores de bet e composições farmacêuticas compreendendo os mesmos
KR20220119088A (ko) Kras 돌연변이체 단백질 억제제
HK1218119B (en) Certain protein kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230629

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230629

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240305

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240401

R150 Certificate of patent or registration of utility model

Ref document number: 7465945

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150